Literature DB >> 24240151

Influenza vaccines: mTOR inhibition surprisingly leads to protection.

Andrew J McMichael1, Barton F Haynes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24240151     DOI： 10.1038/ni.2764

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  13 in total

Review 1.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses.

Authors:  Jonathan W Yewdell
Journal:  Immunity       Date:  2006-10       Impact factor: 31.745

2.  Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.

Authors:  R R Garrity; G Rimmelzwaan; A Minassian; W P Tsai; G Lin; J J de Jong; J Goudsmit; P L Nara
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

Review 3.  Evolutionary and somatic selection of the antibody repertoire in the mouse.

Authors:  K Rajewsky; I Förster; A Cumano
Journal:  Science       Date:  1987-11-20       Impact factor: 47.728

Review 4.  Immunology taught by viruses.

Authors:  R M Zinkernagel
Journal:  Science       Date:  1996-01-12       Impact factor: 47.728

5.  Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Authors:  James R R Whittle; Ruijun Zhang; Surender Khurana; Lisa R King; Jody Manischewitz; Hana Golding; Philip R Dormitzer; Barton F Haynes; Emmanuel B Walter; M Anthony Moody; Thomas B Kepler; Hua-Xin Liao; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

6.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.

Authors:  M I Chiu; H Katz; V Berlin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 7.  HIV-1 neutralizing antibodies: understanding nature's pathways.

Authors:  John R Mascola; Barton F Haynes
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

8.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

Authors:  E J Brown; M W Albers; T B Shin; K Ichikawa; C T Keith; W S Lane; S L Schreiber
Journal:  Nature       Date:  1994-06-30       Impact factor: 49.962

9.  How can vaccines against influenza and other viral diseases be made more effective?

Authors:  Peter L Nara; Gregory J Tobin; A Ray Chaudhuri; Jessie D Trujillo; George Lin; Michael W Cho; Simon A Levin; Wilfred Ndifon; Ned S Wingreen
Journal:  PLoS Biol       Date:  2010-12-21       Impact factor: 8.029

10.  The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus.

Authors:  Rachael Keating; Tomer Hertz; Marie Wehenkel; Tarsha L Harris; Benjamin A Edwards; Jennifer L McClaren; Scott A Brown; Sherri Surman; Zachary S Wilson; Philip Bradley; Julia Hurwitz; Hongbo Chi; Peter C Doherty; Paul G Thomas; Maureen A McGargill
Journal:  Nat Immunol       Date:  2013-10-20       Impact factor: 25.606
View more
  3 in total

1.  mTOR inhibitors for treatment of low-risk prostate cancer.

Authors:  Michael A Liss; Lanette Rickborn; John DiGiovanni; Dean Bacich; Linda A DeGraffenried; Manish Parihar; Ian M Thompson; Zelton Dave Sharp
Journal:  Med Hypotheses       Date:  2018-06-05       Impact factor: 1.538

Review 2.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

Review 3.  Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host.

Authors:  Jian Zheng; Stanley Perlman
Journal:  Curr Opin Virol       Date:  2017-11-21       Impact factor: 7.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.